Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of VR942 in Healthy Volunteers and Mild Asthmatics
NCT02473939Phase 1Completed
- Sponsor
- Vectura
- Start
- Jun 2015
- Primary completion
- Apr 2016
- Modality
- Antibody Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of abrezekimab in asthma (5 arms), sponsored by Vectura. Primary endpoint: Number of participants with adverse events at 28 days. Started Jun 2015; status: completed.
02
Drugs
abrezekimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02473939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02473939.